In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nuclear Pharmacy Services

Division of Cardinal Health Inc.

Latest From Nuclear Pharmacy Services

Healthy Convergence

Some health care firms have managed to work around the industry's well-documented growth constraints by pursuing a strategy of convergence--finding new combinations of formerly distinct market segments for pharmaceuticals, devices, and diagnostics. The authors, at Bain & Company, outline the considerations that drive the evaluation of and set the stage for convergence opportunities. Companies can use them to capitalize on an array of opportunities throughout the commercialization continuum and develop a response to potential threats from the outside.

BioPharmaceutical Medical Device

Launching Zevalin

The market success of Zevalin, Idec Pharmaceutical's second product will largely depend on how well the company has built the requisite commercial infrastructure prior to launch. Idec benefited from having watched how Genentech handled the launch of Idec's first drug, Rituxan. But Zevalin raises unique issues including the need to establish a logistical framework for this first-of-its-kind regimen, in which radiation oncologists play a significant role in the therapy. A disappointment would heighten the uncertainty around the launch of other kinds of innovative products--Idec's certainly, and also those of other companies. The industry will be watching this as a barometer of potential for whether other highly complex therapies whose delivery entails the use of several types of specialists can succeed.

BioPharmaceutical Medical Device

Imaging in its Heyday: Clinical Applications (Part II)

As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.

Medical Device Business Strategies

Imaging Diagnostic Systems Inc.

Diagnostic Imaging; Breast Cancer. Imaging Diagnostic Systems is developing a breast imaging device that uses laser technology instead of traditional x-rays to scan the breast. The company claims its {Computer Tomography Laser Mammography} technology should enable radiologists to spot tumors as small as 2 millimeters in diameter. It may also be able to identify masses as benign or malignant.

Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Syncor International Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cardinal Health Inc.
  • Senior Management
  • James M Usdan, Pres. & CEO
    William P Forster, SVP, CFO
    Mike Fenerin, VP, Mktg.
    Tim Guttman, VP, Fin.
  • Contact Info
  • Nuclear Pharmacy Services
    Phone: (818) 737-4000
    6464 Canoga St.
    Woodland Hills, CA 91367